Suppr超能文献

微小染色体维持蛋白2的表达作为弥漫性大B细胞淋巴瘤增殖和预后的标志物:组织芯片及临床病理分析

Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis.

作者信息

Obermann Ellen C, Went Philip, Zimpfer Annette, Tzankov Alexandar, Wild Peter J, Stoehr Robert, Pileri Stefano A, Dirnhofer Stephan

机构信息

Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany.

出版信息

BMC Cancer. 2005 Dec 20;5:162. doi: 10.1186/1471-2407-5-162.

Abstract

BACKGROUND

Minichromosome maintenance (MCM) proteins are essential for the initiation of DNA replication and have been found to be relevant markers for prognosis in a variety of tumours. The aim of this study was to assess the proliferative activity of diffuse large B-cell lymphoma (DLBCL) in tissue microarray (TMA) using one of the minichromosome maintenance proteins (Mcm2) and to explore its potential value to predict prognosis.

METHODS

Immunohistochemistry for Mcm2 was performed on TMAs constructed from 302 cases of DLBCL. A monoclonal mouse antibody was used after heat induced antigen retrieval. Mcm2 expression was scored quantitatively. Positivity for Mcm2 was defined as presence of nuclear expression of Mcm2 in greater than or equal to 40 % of tumour cells. A statistical analysis was carried out of the association of Mcm2 and the clinico-pathological characteristics.

RESULTS

Mcm2 expression was clearly evident in the nuclei of proliferating non-neoplastic cells and tumour cells. Positivity for Mcm2 was found in 46% (98/211) of analysable cases. A significant correlation existed between Mcm2 expression and presence of bulky disease (p = 0.003). Poor disease specific survival was observed in patients with DLBCL positive for Mcm2 expression in the univariate analysis (p = 0.0424).

CONCLUSION

Mcm2 expression can be used to assess tumour proliferation and may be useful as an additional prognostic marker to refine the prediction of outcome in DLBCL.

摘要

背景

微小染色体维持(MCM)蛋白对于DNA复制的起始至关重要,并且已被发现是多种肿瘤预后的相关标志物。本研究的目的是使用微小染色体维持蛋白之一(Mcm2)评估组织芯片(TMA)中弥漫性大B细胞淋巴瘤(DLBCL)的增殖活性,并探讨其预测预后的潜在价值。

方法

对由302例DLBCL构建的TMA进行Mcm2免疫组织化学检测。热诱导抗原修复后使用单克隆小鼠抗体。对Mcm2表达进行定量评分。Mcm2阳性定义为在大于或等于40%的肿瘤细胞中存在Mcm2核表达。对Mcm2与临床病理特征的相关性进行统计分析。

结果

Mcm2表达在增殖的非肿瘤细胞和肿瘤细胞核中明显可见。在46%(98/211)的可分析病例中发现Mcm2阳性。Mcm2表达与大包块病的存在之间存在显著相关性(p = 0.003)。在单因素分析中,Mcm2表达阳性的DLBCL患者观察到较差的疾病特异性生存率(p = 0.0424)。

结论

Mcm2表达可用于评估肿瘤增殖,并且可能作为一种额外的预后标志物,有助于完善DLBCL预后的预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e673/1343577/9ca38ab72380/1471-2407-5-162-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验